Insulin Resistance and Androgen Deprivation Therapy
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
Prostate cancer is the most common malignancy amongst men in United States. Androgen
deprivation therapy (ADT) with long acting gonadotropin releasing hormone agonists is
routinely used as adjuvant therapy in intermediate and high risk localized or locally
advanced prostate cancer. Since ADT induces insulin resistance and diabetes, it is important
that cellular and molecular effects of ADT are investigated to define precisely the
mechanisms involved in the pathogenesis of insulin resistance. Pioglitazone, a known insulin
sensitizer, may provide amelioration of insulin resistance in these patients.